Código QR

A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

Abstract Objectives HER2 is an infrequently mutated driver gene in non‐small cell lung cancer (NSCLC). At present, there has been no comprehensive large‐scale clinical study to establish the optimal first‐line treatment strategy for advanced lung adenocarcinoma (LUAD) with HER2‐Mutant. Besides that,...

Descrición completa

Gardado en:
Principais autores: Li Wang, Yueran Wu, Zhixuan Ren, Xiangling Chu, Jianing Chen, Li Liu, Jing Zhao, Xin Yu, Mengqing Xie, Chunxia Su
Formato: Artigo
Idioma:Inglês
Publicado: Wiley 2024-06-01
Series:Cancer Medicine
Assuntos:
efficacy
first‐line treatment
HER2‐mutant
lung adenocarcinoma
pyrotinib
Acceso en liña:https://doi.org/10.1002/cam4.7335
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares